Please login to the form below

Not currently logged in

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Acquisition bolsters immuno-oncology pipeline


On the eve of an update for investors, Sanofi has agreed to buy US biotech Synthorx for around $2.5bn in cash, bolstering its immuno-oncology pipeline.

The French drugmaker is paying $68 per share for Synthorx – a 172% premium on the biotech’s closing share price on Friday – bolting on a pipeline of ‘synthorin’ drugs for cancer as well as autoimmune indications, headed by a drug for solid tumours that is in a phase 1 trial.

New Sanofi CEO Paul Hudson (pictured below) was recently reported to be looking into a possible sale or spinout of Sanofi’s consumer health operations as well as other divestments – following a path trodden by the likes of AstraZeneca and Pfizer – in order to raise cash for internal R&D and bolt-on deals to boost the pipeline.

Paul Hudson

Sanofi CEO Paul Hudson

The deal is “aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations”, said Hudson.

The Synthorx deal is his first play, and adds a technology platform that came out of the lab of Dr Floyd Romesberg of the Scripps Research Institute. Synthorins are proteins that are modified using a base pair technique to improve their characteristics.

Lead candidate THOR-707 is a pegylated, modified version of interleukin-2 (IL-2) that is being tested against multiple tumour types, and will be tested in combination with Sanofi’s current cancer drugs.

The modification extends the time the drug stays in the body compared to regular IL-2 or aldesleukin – which has been used for years to treat melanoma and kidney cancer – but also blocks side effects such as vascular leak syndrome (VLS) which can be fatal and limit IL-2’s usefulness.

Sanofi is a bit of a latecomer to the cancer immunotherapy category but claimed approval earlier this year for Libtayo (cemiplimab) – the sixth PD-1/PD-L1 inhibitor to reach the market – as a treatment for cutaneous Libtayosquamous cell carcinoma (CSCC).

The Regeneron-partnered drug is the first drug in the checkpoint inhibitor class to get a green light in that type of skin cancer, and is also being tested in head and neck, colorectal and prostate tumours, as well as melanoma and blood cancers.

Sanofi and Regeneron are also working on bispecific antibody immunotherapies, including two lead candidate targeting BCMA/CD3 and MUC/CD3, respectively.

Sanofi has had a challenging few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma drug Dupixent (dupilumab) – but also failures such as dengue vaccine Dengvaxia and underperforming cholesterol drug Praluent (alirocumab).

Article by
Phil Taylor

10th December 2019

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....